Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
ANTH's Cash-to-Debt is ranked higher than
80% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. ANTH: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ANTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 5001.38 Max: No Debt
Current: No Debt
Interest Coverage No Debt
ANTH's Interest Coverage is ranked higher than
79% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANTH: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ANTH' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: -29.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2771.55
ANTH's Operating Margin % is ranked lower than
85% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. ANTH: -2771.55 )
Ranked among companies with meaningful Operating Margin % only.
ANTH' s Operating Margin % Range Over the Past 10 Years
Min: -39432.41  Med: -20269.47 Max: -1106.53
Current: -2771.55
-39432.41
-1106.53
Net Margin % -2691.37
ANTH's Net Margin % is ranked lower than
86% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. ANTH: -2691.37 )
Ranked among companies with meaningful Net Margin % only.
ANTH' s Net Margin % Range Over the Past 10 Years
Min: -38291.72  Med: -19698.77 Max: -1105.81
Current: -2691.37
-38291.72
-1105.81
ROE % -289.57
ANTH's ROE % is ranked lower than
93% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. ANTH: -289.57 )
Ranked among companies with meaningful ROE % only.
ANTH' s ROE % Range Over the Past 10 Years
Min: -582.71  Med: -259.55 Max: -179.7
Current: -289.57
-582.71
-179.7
ROA % -158.05
ANTH's ROA % is ranked lower than
90% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ANTH: -158.05 )
Ranked among companies with meaningful ROA % only.
ANTH' s ROA % Range Over the Past 10 Years
Min: -414.89  Med: -145.89 Max: -94.5
Current: -158.05
-414.89
-94.5
ROC (Joel Greenblatt) % -9353.61
ANTH's ROC (Joel Greenblatt) % is ranked lower than
86% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. ANTH: -9353.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANTH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -263793.33  Med: -12857.08 Max: -2880.94
Current: -9353.61
-263793.33
-2880.94
3-Year EBITDA Growth Rate -4.30
ANTH's 3-Year EBITDA Growth Rate is ranked lower than
54% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. ANTH: -4.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANTH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -54.8 Max: -4.3
Current: -4.3
3-Year EPS without NRI Growth Rate -1.60
ANTH's 3-Year EPS without NRI Growth Rate is ranked higher than
51% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. ANTH: -1.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ANTH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -54 Max: -1.6
Current: -1.6
GuruFocus has detected 1 Warning Sign with Anthera Pharmaceuticals Inc $ANTH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ANTH Guru Trades in Q2 2015

Jim Simons Sold Out
» More
Q3 2015

ANTH Guru Trades in Q3 2015

Jim Simons 169,000 sh (New)
» More
Q4 2015

ANTH Guru Trades in Q4 2015

Jim Simons 269,000 sh (+59.17%)
» More
Q1 2016

ANTH Guru Trades in Q1 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RTTR, NAS:GALE, OTCPK:BRTX, NAS:ONTX, NAS:ARGS, NAS:PRAN, OTCPK:MRNA, NAS:CYAN, NAS:CERU, NAS:NEOT, NAS:EYEG, OTCPK:NULF, OTCPK:DMCAF, NAS:ACST, NAS:HTBX, OTCPK:MATN, NAS:TKAI, OTCPK:RGIN, OTCPK:SRBCF, OTCPK:PTIX » details
Traded in other countries:6TA1.Germany,
Anthera Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases.

Anthera Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.

Ratios

vs
industry
vs
history
PB Ratio 4.68
ANTH's PB Ratio is ranked higher than
87% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ANTH: 4.68 )
Ranked among companies with meaningful PB Ratio only.
ANTH' s PB Ratio Range Over the Past 10 Years
Min: 2.69  Med: 6.21 Max: 21.41
Current: 4.68
2.69
21.41
PS Ratio 107.50
ANTH's PS Ratio is ranked lower than
66% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. ANTH: 107.50 )
Ranked among companies with meaningful PS Ratio only.
ANTH' s PS Ratio Range Over the Past 10 Years
Min: 29.67  Med: 120 Max: 680
Current: 107.5
29.67
680
Current Ratio 2.14
ANTH's Current Ratio is ranked lower than
72% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ANTH: 2.14 )
Ranked among companies with meaningful Current Ratio only.
ANTH' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 1.74 Max: 8.15
Current: 2.14
0.21
8.15
Quick Ratio 2.14
ANTH's Quick Ratio is ranked lower than
68% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ANTH: 2.14 )
Ranked among companies with meaningful Quick Ratio only.
ANTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.21  Med: 1.74 Max: 8.15
Current: 2.14
0.21
8.15

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.30
ANTH's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ANTH: -29.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANTH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -274  Med: -59.3 Max: 0
Current: -29.3
-274
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.87
ANTH's Price-to-Net-Cash is ranked higher than
93% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. ANTH: 1.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ANTH' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.74  Med: 4.83 Max: 18.06
Current: 1.87
1.74
18.06
Price-to-Net-Current-Asset-Value 6.14
ANTH's Price-to-Net-Current-Asset-Value is ranked higher than
61% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. ANTH: 6.14 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ANTH' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.8  Med: 9.29 Max: 16.16
Current: 6.14
2.8
16.16
Price-to-Tangible-Book 4.78
ANTH's Price-to-Tangible-Book is ranked higher than
59% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ANTH: 4.78 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ANTH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.8  Med: 4.68 Max: 13.18
Current: 4.78
2.8
13.18
Price-to-Median-PS-Value 0.90
ANTH's Price-to-Median-PS-Value is ranked higher than
75% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ANTH: 0.90 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ANTH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.89 Max: 1.35
Current: 0.9
0.43
1.35
Earnings Yield (Greenblatt) % -232.56
ANTH's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. ANTH: -232.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ANTH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -281.23  Med: 2532.7 Max: 41750.6
Current: -232.56
-281.23
41750.6

More Statistics

Revenue (TTM) (Mil) $2.06
EPS (TTM) $ -1.61
Beta2.59
Short Percentage of Float13.68%
52-Week Range $0.38 - 4.40
Shares Outstanding (Mil)50.61

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.38 -1.57 -0.81
EPS without NRI ($) -1.38 -1.57 -0.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ANTH

Headlines

Articles On GuruFocus.com
Is AzurRx About to Transform the Gastrointestinal Treatment Industry? Jan 05 2017 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 12 2010 
Weekly CFO Buys Highlight: Inuvo Inc., Heelys Inc., Peregrine Pharmaceuticals Inc., Anthera Pharmace Sep 26 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 12 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Will Endo's Troubles Continue to Dent Performance in 2017? Mar 28 2017
ETFs with exposure to Anthera Pharmaceuticals, Inc. : March 27, 2017 Mar 27 2017
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation Mar 23 2017
ANTHERA PHARMACEUTICALS INC Financials Mar 23 2017
Anthera Pharmaceuticals, Inc. :ANTH-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017 Mar 21 2017
Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2% Mar 21 2017
ANTH INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Mar 20 2017
Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3% Mar 20 2017
Implied Volatility Surging for Anthera (ANTH) Stock Options Mar 17 2017
Shire's (SHPG) Cinryze Label Expanded for Pediatric Use Mar 16 2017
Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA Mar 16 2017
Guess, Anthera Pharmaceuticals Dive into Thursday’s 52-Week Low Club Mar 16 2017
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Mar 16 2017
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline Mar 16 2017
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Mar 14 2017
Valeant, JC Penney Plunge Into Tuesday’s 52-Week Low Club Mar 14 2017
ANTH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action... Mar 14 2017
Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and... Mar 14 2017
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants Mar 13 2017
New Strong Buy Stocks for March 8th Mar 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)